Market capitalization | $127.29m |
Enterprise Value | $81.18m |
EV/Sales (TTM) EV/Sales | 0.96 |
P/S ratio (TTM) P/S ratio | 1.50 |
Short interest | 0.32% |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Genetron Holdings Ltd - ADR:
1 Analyst has issued a forecast Genetron Holdings Ltd - ADR:
Dec '22 |
+/-
%
|
||
Revenue | 97 97 |
17%
17%
|
|
Gross Profit | 42 42 |
20%
20%
|
|
EBITDA | -92 -92 |
29%
29%
|
EBIT (Operating Income) EBIT | -104 -104 |
28%
28%
|
Net Profit | -120 -120 |
56%
56%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Head office | Cayman Islands |
CEO | Si Wang |
Founded | 2015 |
Website | ir.genetronhealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.